Pradžia › Sklerodermija › Kalifornija
Sklerodermija klinikiniai tyrimai Kalifornija
13 tyrimai dėl Sklerodermija ieško dalyvių vietose Kalifornija.
Miestai Kalifornija
Oficialus tyrimo tekstas (anglų kalba)
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- University of California Los Angeles, Los Angeles
- Paradigm Clinical Research - San Diego, San Diego
- Stanford University School of Medicine, Stanford
- ir dar 1
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-30 · NCT07497087A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
- UCLA Ronald Reagan University of California Los Angeles Medical Center, Los Angeles
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-24 · NCT06655155Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- University of California Davis Comprehensive Cancer Center, Sacramento
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-23 · NCT03816345A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Loma Linda University Medical Center, Loma Linda
Renkami dalyviai1 fazė
Amžius nuo 18 iki 74 · Visoms lytims · Atnaujinta 2026-09-10 · NCT07085104A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
- ir dar 1
Renkami dalyviai2/3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-08 · NCT05878717FT839 in Autoimmune Diseases
- Providence Medical Foundation, Fullerton
Renkami dalyviai1/2 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-09-02 · NCT07800871A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- UC San Diego Health, La Jolla
- Stanford University Medical Center, Redwood City
Renkami dalyviai1 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-08-28 · NCT06925542Platform Clinical Study for Conquering Scleroderma
- Keck School of Medicine at USC Medical Center, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- Stanford University Medical Center, Palo Alto
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-18 · NCT06195072A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Orange
Renkami dalyviai1/2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-08-07 · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Chula Vista, Chula Vista
- Artiva Investigational Site Covina, Covina
- Artiva Investigational Site Los Alamitos, Los Alamitos
- ir dar 3
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-31 · NCT06991114A Study of AZD0120 in Autoimmune Diseases
- Research Site, Stanford
Renkami dalyviai1 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-07-28 · NCT07295847A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Wallace Rheumatic Center, Beverly Hills
- Providence Medical Foundation, Fullerton
- University of California Irvine, Irvine
- ir dar 2
Renkami dalyviai1 fazė
Amžius nuo 12 iki 70 · Visoms lytims · Atnaujinta 2026-05-22 · NCT06308978Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, Los Angeles
- aTyr Investigative Site, San Diego
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-05-07 · NCT05892614Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.